HomeUCB • EBR
add
UCB SA
Previous close
€124.55
Day range
€119.80 - €124.15
Year range
€65.40 - €125.25
Market cap
23.80B EUR
Avg Volume
307.01K
P/E ratio
69.63
Dividend yield
0.78%
Primary exchange
EBR
Market news
Financials
Income Statement
Revenue
Net income
| (EUR) | Dec 2023info | Y/Y change |
|---|---|---|
Revenue | 1.33B | — |
Operating expense | 796.50M | — |
Net income | 16.00M | — |
Net profit margin | 1.20 | — |
Earnings per share | — | — |
EBITDA | 270.50M | — |
Effective tax rate | 20.00% | — |
Balance Sheet
Total assets
Total liabilities
| (EUR) | Dec 2023info | Y/Y change |
|---|---|---|
Cash and short-term investments | 923.00M | -2.43% |
Total assets | 15.54B | -2.07% |
Total liabilities | 6.56B | -3.53% |
Total equity | 8.98B | — |
Shares outstanding | 189.75M | — |
Price to book | 2.63 | — |
Return on assets | 1.33% | — |
Return on capital | 1.72% | — |
Cash Flow
Net change in cash
| (EUR) | Dec 2023info | Y/Y change |
|---|---|---|
Net income | 16.00M | — |
Cash from operations | 256.00M | — |
Cash from investing | -83.50M | — |
Cash from financing | 29.50M | — |
Net change in cash | 202.50M | — |
Free cash flow | 196.56M | — |
About
UCB is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease. The company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system disorders, inflammatory disorders, and oncology.
Every three years, the company presents the UCB Award under the patronage of the Queen Elisabeth Medical Foundation to promote neuroscience research. The winner of this award is selected by an independent scientific committee. Wikipedia
Founded
Jan 18, 1928
Website
Employees
8,767
